| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051262493 |
| P356 | DOI | 10.1007/S11892-016-0728-4 |
| P698 | PubMed publication ID | 27037706 |
| P2093 | author name string | Hui Peng | |
| Vanita R Aroda | |||
| Laura L Want | |||
| P2860 | cites work | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies | Q24568148 | ||
| One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 | ||
| Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies | Q28175267 | ||
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 | ||
| Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 | ||
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial | Q28286240 | ||
| Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial | Q28287325 | ||
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| Pancreatic safety of incretin-based drugs--FDA and EMA assessment | Q28308049 | ||
| Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats | Q28570878 | ||
| Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists | Q33521451 | ||
| Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes | Q33558150 | ||
| Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks | Q33585633 | ||
| Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study | Q33606579 | ||
| Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin | Q33804747 | ||
| Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years | Q33884913 | ||
| Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study | Q34035766 | ||
| Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis | Q34237350 | ||
| Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials | Q34401433 | ||
| A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. | Q34421364 | ||
| Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies | Q34627077 | ||
| Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis | Q34648377 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study | Q35688369 | ||
| Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans | Q35769564 | ||
| Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials | Q35780935 | ||
| The cardiovascular effects of GLP-1 receptor agonists | Q36368998 | ||
| Exenatide (exendin-4)-induced pancreatitis: a case report. | Q54453692 | ||
| Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study | Q59624425 | ||
| Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes | Q59624449 | ||
| Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment | Q59942672 | ||
| Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide | Q61836852 | ||
| Glucagon-like peptide containing pathways in the regulation of feeding behaviour | Q77628411 | ||
| A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects | Q85022198 | ||
| Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas | Q85301428 | ||
| Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study | Q36420499 | ||
| Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population | Q36444054 | ||
| Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes | Q36498695 | ||
| Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects | Q36729921 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. | Q37349800 | ||
| Exenatide efficacy and safety: a systematic review | Q37589672 | ||
| Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study | Q37728819 | ||
| A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes | Q37771195 | ||
| Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies | Q37824904 | ||
| A cohort study of acute pancreatitis in relation to exenatide use. | Q37841739 | ||
| The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review | Q37864256 | ||
| The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials | Q37988080 | ||
| Hypoglycemia: minimizing its impact in type 2 diabetes | Q38083121 | ||
| An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes | Q38427409 | ||
| Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. | Q38450276 | ||
| GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. | Q39030156 | ||
| Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. | Q39732229 | ||
| Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study | Q39905736 | ||
| DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks | Q40718093 | ||
| Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years | Q42091988 | ||
| GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide | Q42482163 | ||
| Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia | Q42613301 | ||
| On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. | Q42712582 | ||
| Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. | Q42914212 | ||
| Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats | Q44598041 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Exenatide and acute pancreatitis | Q46074007 | ||
| Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study | Q46357275 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial | Q46834147 | ||
| Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers | Q46849966 | ||
| Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years | Q46870991 | ||
| A pooled analysis of exenatide use and risk of acute pancreatitis. | Q46963914 | ||
| Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Q47333592 | ||
| Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus | Q47333601 | ||
| Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model | Q47358839 | ||
| Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. | Q48071098 | ||
| Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. | Q48218648 | ||
| Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. | Q48714353 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. | Q51473976 | ||
| A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. | Q51483637 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 44 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Current diabetes report | Q26841965 |
| P1476 | title | Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program | |
| P478 | volume | 16 |
| Q38810840 | Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop |
| Q37639310 | Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial |
| Q37427294 | Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials |
| Q91361813 | Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon |
| Q90256243 | Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease |
| Q31167862 | Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. |
| Q39140474 | Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review. |
| Q47864001 | Sitagliptin Treatment After Total Pancreatectomy With Islet Autotransplantation: A Randomized, Placebo-Controlled Study |
Search more.